CommercialCoverageHigh impact
Polymerase Chain Reaction Testing: Selected Indications (CPB 0650, reviewed 2026-01-27)
Aetna·Infectious Disease, Oncology, Pathology +7 more·Medical Policy
Effective date
Jan 27, 2026
We identified it
Aug 13, 2026
Summary
Aetna has updated CPB 0650 (effective 2026-01-27) establishing comprehensive medical necessity criteria for qualitative and quantitative PCR testing across numerous infectious diseases, genetic conditions, and oncology applications. This policy clarifies which PCR tests are covered and which specimen types are acceptable, with specific exclusions for certain indications (e.g., urine PCR for bacterial vaginosis, asymptomatic male partner testing). Billing teams must verify PCR test orders against this detailed approved indications list to prevent claim denials.
Action Required
By 2026-01-27: Billing and coding teams must implement the following: (1) Cross-reference all incoming PCR test orders against the Aetna CPB 0650 approved indications list before submission; (2) Deny or request modification for non-approved indications including: urine PCR for bacterial vaginosis, asymptomatic male sex partner testing for BV, urine PCR for candidiasis, and PCR testing for COVID-19 required for work/school/recreational activities; (3) Update billing system rules to flag and require provider documentation for conditional approvals (e.g., avian flu requiring both symptoms AND travel history within 10 days, pertussis requiring symptoms within 21 days); (4) Train front-end and coding staff to verify specimen type matches policy requirements (e.g., vaginal swabs for BV/candidiasis, not urine); (5) Create internal lookup table or system alert mapping the 50+ approved conditions to their specific medical necessity criteria; (6) Route borderline cases (e.g., B. miyamotoi testing, Borrelia mayonii testing) to clinical review before billing. Claims submitted without documented medical necessity per this policy will face denial. Billing team should flag any orders lacking required clinical documentation (e.g., travel history, symptom onset dates, specimen types) for provider clarification before claim submission.